Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
68
KYMR Quote, Financials, Valuation and Earnings
Last price:
$90.10
Seasonality move
:
-21.77%
Day range:
$88.80 - $93.99
52-week range:
$19.45 - $103.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
196.75x
P/B ratio:
4.16x
Volume:
1.2M
Avg. volume:
806.4K
1-year change:
201.98%
Market cap:
$6.6B
Revenue:
$39.2M
EPS (TTM):
-$3.68
Analysts' Opinion
-
Consensus RatingKymera Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 17 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $118.00, Kymera Therapeutics, Inc. has an estimated upside of 28.39% from its current price of $91.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $90.00 representing 1.48% downside risk from its current price of $91.35.
Fair Value
-
According to the consensus of 18 analysts, Kymera Therapeutics, Inc. has 28.39% upside to fair value with a price target of $118.00 per share.
KYMR vs. S&P 500
-
Over the past 5 trading days, Kymera Therapeutics, Inc. has overperformed the S&P 500 by 4.99% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kymera Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kymera Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Kymera Therapeutics, Inc. reported revenues of $2.9M.
Earnings Growth
-
Kymera Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Kymera Therapeutics, Inc. reported earnings per share of -$0.97.
Enterprise value:
5.8B
EV / Invested capital:
3.49x
Price / LTM sales:
196.75x
EV / EBIT:
--
EV / Revenue:
148.09x
PEG ratio (5yr expected):
-1.03x
EV / Free cash flow:
-24.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$30.9M
Return On Assets:
-26.51%
Net Income Margin (TTM):
-794.06%
Return On Equity:
-30.41%
Return On Invested Capital:
-28.07%
Operating Margin:
-3411.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $78.6M | $47.1M | $39.2M | $7.4M | $2.9M | |
| Gross Profit | $75M | $39.7M | $30.9M | $5.4M | $838K | |
| Operating Income | -$165.5M | -$256.7M | -$345.5M | -$80.8M | -$97.9M | |
| EBITDA | -$162M | -$249.3M | -$337.2M | -$78.8M | -$95.9M | |
| Diluted EPS | -$2.52 | -$2.97 | -$3.68 | -$0.88 | -$0.97 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $451.3M | $419.4M | $405.3M | $510.3M | $871.2M | |
| Total Assets | $605.9M | $603.1M | $575.8M | $978M | $1.7B | |
| Current Liabilities | $92.5M | $71.3M | $85.7M | $67.8M | $83.2M | |
| Total Liabilities | $146.3M | $113M | $180.8M | $142.4M | $163.1M | |
| Total Equity | $459.6M | $490.2M | $395M | $835.6M | $1.6B | |
| Total Debt | $15.5M | $14.8M | $79.6M | $76.2M | $70.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$102.8M | -$194.5M | -$232.9M | -$61.8M | -$66.7M | |
| Cash From Investing | $139.9M | -$404.1M | -$521.1M | $68.6M | -$394.4M | |
| Cash From Financing | $4.2M | $608.9M | $990.7M | $2.8M | $705.2M | |
| Free Cash Flow | -$137.3M | -$207.3M | -$234.3M | -$62.7M | -$66.9M | |
KYMR
Sector
Market Cap
$6.6B
$25.5M
Price % of 52-Week High
88.69%
50%
Dividend Yield
0%
0%
Shareholder Yield
-17.7%
-1.62%
1-Year Price Total Return
201.98%
-18.12%
Beta (5-Year)
2.205
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$89.44
200-day SMA
Buy
Level
$57.83
Bollinger Bands (100)
Buy
Level
61.35 - 82.61
Chaikin Money Flow
Buy
Level
23.1M
20-day SMA
Buy
Level
$83.31
Relative Strength Index (RSI14)
Buy
Level
66.75
ADX Line
Buy
Level
23.45
Williams %R
Neutral
Level
-23.4718
50-day SMA
Buy
Level
$78.86
MACD (12, 26)
Buy
Level
4.45
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
40.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.6432)
Buy
CA Score
(Annual)
Level (0.1804)
Buy
Beneish M-Score
(Annual)
Level (-3.009)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.1323)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, KYMR has received 17 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KYMR average analyst price target in the past 3 months is $118.00.
-
Where Will Kymera Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kymera Therapeutics, Inc. share price will rise to $118.00 per share over the next 12 months.
-
What Do Analysts Say About Kymera Therapeutics, Inc.?
Analysts are divided on their view about Kymera Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kymera Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $90.00.
-
What Is Kymera Therapeutics, Inc.'s Price Target?
The price target for Kymera Therapeutics, Inc. over the next 1-year time period is forecast to be $118.00 according to 18 Wall Street analysts, 17 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KYMR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kymera Therapeutics, Inc. is a Buy. 17 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KYMR?
You can purchase shares of Kymera Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kymera Therapeutics, Inc. shares.
-
What Is The Kymera Therapeutics, Inc. Share Price Today?
Kymera Therapeutics, Inc. was last trading at $90.10 per share. This represents the most recent stock quote for Kymera Therapeutics, Inc.. Yesterday, Kymera Therapeutics, Inc. closed at $91.35 per share.
-
How To Buy Kymera Therapeutics, Inc. Stock Online?
In order to purchase Kymera Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KYMR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KYMR
Sector
P/E ratio
--
23.08x
PEG ratio
-1.03x
-0.01x
P/B ratio
4.16x
1.81x
Price / LTM sales
196.75x
1.54x
Growth Metrics
KYMR
Sector
Revenue growth
-61.19%
3.44%
Earnings growth
-9.37%
11.11%
Revenue (5-year growth)
2.87%
6.46%
Earnings forecast
-$0.77
-$0.19
Profitability
KYMR
Sector
Profitability FY 2025
$30.9M
$2.4M
Return on invested capital
-28.07%
-33.43%
Return on assets
-26.51%
-29.79%
Return on equity
-30.41%
-39.31%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
8
Estimated Next Earnings Date
May
28
Balance Sheet
KYMR
Sector
Total cash
$848.3M
$24.1M
Short term investments
$368.5M
$23.8M
Total assets
$1.7B
$70.2M
Long term debt
$70.3M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
